Texbraska - thanks for the post - 

See bolded italics below from report conclusion

6. Conclusion

Apabetalone has a dual anti-viral and anti-inflammatory mechanism (Fig. 7) that positions it as a “variant-independent COVID therapeutic” with the potential to counter short- and long-term pathologic consequences caused by SARS-CoV-2 and variants of concern. The safety and efficacy of apabetalone to mitigate serious outcomes in high risk COVID-19 outpatients will be further assessed in an upcoming clinical trial. The ability of apabetalone to alleviate post-COVID syndrome associated with deleterious inflammatory responses will be the subject of future clinical evaluation.

The report went on to say that this research received no external funding. If there is a market for post Covid therapies then this is still alive. This trial should certainly be shorter and less dilutive than BOM2. Let's get on with it.